AMENDED AND RESTATED RESEARCH COLLABORATION AND LICENCE AGREEMENT RELATING TO GENE EDITING AND HLA-ENGINEERING TECHNOLOGYResearch Collaboration and License Agreement • February 27th, 2020 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England
Contract Type FiledFebruary 27th, 2020 Company Industry JurisdictionThis AMENDED AND RESTATED RESEARCH COLLABORATION AND LICENCE AGREEMENT (the “Agreement”) is made as of the 25th day of November 2015 (the “Effective Date”) and amended as of January 13, 2020 (the “Amendment Date”) by and between:
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN UNIVERSAL CELLS, INC. ADAPTIMMUNE LIMITEDCollaboration and License Agreement • February 27th, 2020 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 27th, 2020 Company Industry JurisdictionTHIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated January 13, 2020 (the “Effective Date”) is by and between UNIVERSAL CELLS, INC. a corporation organized and existing under the laws of the state of Washington and having its principal office at 3005 1st Avenue Seattle, WA 98121 (“Universal Cells”) and ADAPTIMMUNE LIMITED, a company incorporated in England and Wales and with its registered address at 101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune”). Each of Universal Cells and Adaptimmune are referred to as a “Party”, and Universal Cells and Adaptimmune are collectively referred to as the “Parties.”
AMENDMENT NO. 1 TO COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT and LICENSE AGREEMENTCommercial Development and Supply Agreement and License Agreement • February 27th, 2020 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledFebruary 27th, 2020 Company IndustryThis Amendment No. 1 to Commercial Development and Supply Agreement (“Amendment No. 1”) effective as of 18 November, 2019 (“Amendment No. 1 Effective Date”) is entered into by and between ADAPTIMMUNE Limited, with offices at 60 Jubilee Avenue (formerly 101 Park Drive), Milton Park, Abingdon, Oxon, OX14 4RX, England (“ADAPTIMMUNE”) and Life Technologies Corporation, an Affiliate of Thermo Fisher Scientific Inc., with offices at 5781 Van Allen Way (formerly 5791), Carlsbad, California 92008 (“LIFE”). and amends the Commercial Development and Supply Agreement effective as of June 1, 2016 entered into by ADAPTIMMUNE and LIFE (“Supply Agreement”). ADAPTIMMUNE and LIFE each hereinafter a “Party” and collectively “Parties”.